Elamipretide

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 179 publications

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Journal: Sports medicine (Auckland, N.Z.)

Published: March 24, 2026

Early targets and progressive deterioration in cardiac performance in response to chronically modified cardiac troponin I.

Early targets and progressive deterioration in cardiac performance in response to chronically modified cardiac troponin I.

Journal: American journal of physiology. Heart and circulatory physiology

Published: February 19, 2026

Mitochondria dysfunction and increased expression of WNT5A and BNIP3 in tenocytes obtained from patients with tendinopathy.

Mitochondria dysfunction and increased expression of WNT5A and BNIP3 in tenocytes obtained from patients with tendinopathy.

Journal: JSES international

Published: January 19, 2026

Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.

Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.

Journal: Lung

Published: January 13, 2026

2025 FDA TIDES (Peptides and Oligonucleotides) Harvest.

2025 FDA TIDES (Peptides and Oligonucleotides) Harvest.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 12, 2026

Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.

Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.

Journal: Tissue & cell

Published: January 03, 2026

Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF.

Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF.

Journal: International journal of molecular sciences

Published: December 17, 2025

Mitochondrial Dysfunction: The Cellular Bridge from Emotional Stress to Disease Onset: A Narrative Review.

Mitochondrial Dysfunction: The Cellular Bridge from Emotional Stress to Disease Onset: A Narrative Review.

Journal: Biomolecules

Published: December 16, 2025

Mitochondria-Targeted Peptides and Bilayer Composition Modulate Membrane Electroporation under Elevated Electrochemical Stress.

Mitochondria-Targeted Peptides and Bilayer Composition Modulate Membrane Electroporation under Elevated Electrochemical Stress.

Journal: Langmuir : the ACS journal of surfaces and colloids

Published: December 04, 2025

Real-world disease burden and health care resource utilization for patients with Barth syndrome.

Real-world disease burden and health care resource utilization for patients with Barth syndrome.

Journal: Journal of medical economics

Published: November 21, 2025

New Insights on Mitochondria-Targeted Neurological Drugs.

New Insights on Mitochondria-Targeted Neurological Drugs.

Journal: Biology

Published: November 21, 2025

Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.

Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.

Journal: Drug discoveries & therapeutics

Published: November 19, 2025

Showing 1-12 of 179

Last Updated: 04/28/2026